NCT06616883View on ClinicalTrials.gov

Pharmacokinetics and Safety Profiles After Administration of DA-5221_01 and Co-administration of 5221_01-R1 and DA-5221_01-R2 in Healthy Adult Volunteers

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

November 14, 2024

Study Completion Date

November 18, 2024

Conditions
Healthy
Interventions
DRUG

DA-5221_01

single dose administration (DA-5221\_01 one tablet once a day)

DRUG

DA-5221_01-R1 + DA-5221_01-R2

single dose administration (DA-5221\_01-R1 one tablet once a day + DA-5221\_01-R2 one tablet once a day)

Trial Locations (1)

07590

Bumin Hospital, Seoul

All Listed Sponsors
lead

Dong-A ST Co., Ltd.

INDUSTRY